Jim Wassil | Vice President, Business Unit Lead, Vaccines, Global Health And Value
Pfizer

Jim Wassil, Vice President, Business Unit Lead, Vaccines, Global Health And Value, Pfizer

James Wassil, MBA, MS, is the Business Unit Lead at Pfizer Vaccineswith responsibilities of Health Outcomes, Cost-Effectiveness, Market Access, Tender Procurement and Pricing.
 
James joined Pfizer in 2015 from Novartis, where he was Global Program Head for Meningococcal Vaccines and responsible for overseeing the development of Bexsero®, the company’s recently licensed meningococcal B vaccine and its ABCWY candidate vaccine.  He also led the company’s US launch of Menveo®, a quadrivalent conjugate vaccine to protect against invasive disease caused by the ACWY serogroups of Neisseria meningitidis.
 
Mr. Wassil’s industry experience spans research, development, regulatory affairs, quality, technology transfer, and commercial operations. Prior to joining Novartis in 2008, he was with Merck for 16 years. He began his Merck career in technology transfer, where he helped to develop the company’s hepatitis A and rotavirus vaccines, and later played an integral role in significantly expanding international access to its vaccines serving as the representative to CVI.
 
Mr. Wassil earned a bachelor of science degree in chemistry/biology with high honors from the University of Notre Dame and a master of science degree in bio-organic chemistry and a master of business administration degree, both from Lehigh University.  In 2014, James received the VIVA Award as Novartis’ top scientist in 2014 for development and approval of Bexsero®.  He also was an ACE Finalist (Secretary of State Award for Corporate Excellence) for his role in conducting an effectiveness study of RotaTeq® in Nicaragua.

Appearances:



April 14 Pre-congress Workshop Day @ 10:00

WORKSHOP C: MARKET ACCESS

Market access & regulatory challenges in vaccinesThe market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine.
  • What to do about Vaccine Hesitancy: When the “Facts” and the “Truth” are Discordant
  • Accurately capturing the full benefits of vaccines
  • HTA assessments around the world: What are the key attributes that drive decisions?
  • Regulatory and public health approaches to clinical trial design and interpretation
  • Value based contracting and managed entry agreements – Making sure uncertainties at launch do not hinder market access
  • Industry perspective: Navigating market authorization applications and life cycle management for new vaccines
  • The Gavi Alliance approach to increasing vaccine access in low-income countries; targeting “Healthy Markets” for vaccines in low-income countries
  • Group discussion and Q&A with audience

April 16 Day 2 - 10 Co-conferences @ 16:40

Panel: Capital Investment Decisions: How to strategically plan to ensure sufficient capacity

last published: 11/Apr/19 16:05 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071